Head-to-head evidence
INV-202 vs monlunabant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: CB1 receptor · full Obesity pipeline
INV-202
Developed by Inversago Pharma and partners
NCT05891834 · Phase 2 · completed
Randomized, double-blind Phase 1b trial (n=54) demonstrating significant weight loss with peripheral CB1 inverse agonist (Lancet Diabetes Endocrinol 2025).
monlunabant
Developed by Novo Nordisk
NCT06542536 · Phase 1 · completed
The study was randomized and blinded against placebo, but it was conducted in healthy volunteers rather than people with obesity, and its purpose was pharmacokinetic bridging and safety, not proving a clinical effect. No results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: INV-202's landscape · monlunabant's landscape